Psychopharmacology Maastricht
The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs.
Learn More
Maastricht Psychedelic Symposium
On May 24, the Maastricht Psychedelic Research Team organized a mini-symposium on psychedelics. We welcomed two international speakers: Prof. dos Santos and Prof. Bouso from Brazil and Spain to discuss their ayahuasca and ibogaine research. We also had several internal speakers: presenting on mystical vs. autobiographical psychedelic experiences (Dr Kangaslampi), microdosing (Ms. Haijen), and 5-MeO-DMT (Mr. Reckweg).
Click below to watch the entire symposium
Read about our new paper on the neurological origins of a visual psychedelic hallucination
Congratulations to Zeus Tipado on his newly published paper that introduces a new theory as to why a person experiences a visual trip on psychedelics.
Read The PaperParticipate in our studies!
We're always conducting research in our department and we're frequently looking for participants to be a part of science! If you're interested, look at the studies that we are currently conducting.
View All Studies
Our Scientists
Dr. Natasha Mason
Psychedelics, Neuroadaptations, Plasticity
My research is driven by my desire to find effective treatments for psychiatric disorders, particularly anxiety, depression, and post-traumatic stress disorder.
Dr. Kim Kuypers
Nutrition, Microdosing, Cognition
My research focuses on the neurobiology of flexible cognition, empathy, and well-being.
Janine Kox, MSc
Psychedelics, Cognitive biases, Stress Resilience
My research focuses on the effects of stress, sleep deprivation, on cognitive biases, by using the transdiagnostic rDOC approach, and see whether psychedelics such as LSD, Psilocybin and even non-hallucinogenic psychedelics can reverse these effects.
Dr. Rudy Schreiber
CNS Drug Discovery, Research Domain Criteria
I started my career in central nervous system drug discovery in 1993 and subsequently progressed from bench scientist to senior leadership roles at global pharmaceutical companies
Aedan O’Shea, MSc
I have a long standing interest in unravelling the therapeutic mechanisms of Psychedelics, and in this project I will investigate the effect of Psychedelic drug exposure in humans on miRNA’s transported in neuron-derived Extracellular Vesicles...
Mauro Cavarra, MSc
Psychosomatics, Chronic Pain, Psychedelic-Assisted Psychotherapy
I am a psychotherapist, hypnotherapist and clinical trainer interested in understanding the connection between mind and body. At the Department I work in research projects that explore the potential of psychedelic therapies in the treatment...
Katharina Lege, MSc
Cannabinoids, Neuroimaging, Consciousness
Coming from a background of psychology and clinical neuroscience, I developed a strong interest in altered states of the mind as in mediation or yoga practices.
Zeus Tipado, MSc
My neuroscience research is focused on perceptual experiences of psychedelics, specifically visual experiences while under DMT.
Lorena Guerra, MSc
I am Lorena, a PhD candidate from Brazil with experience working on preclinical and clinical research.
Psychedelic Research
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
→
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life
5-MeO-DMT, naturalistic, psychopathological
→
Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions
tripping, hallucinations, visual, Psychedelics, vision, retinofugal
→
Spontaneous and deliberate creative cognition during and after psilocybin exposure
Cognition, Psilocybin, creativity
→
Cannabis Research
Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity
Cannabis, Glutamate, Functional Connectivity
→
Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users
Psychomotor, Cannabis, Cognition
→
Cognition and motor control as a function of 9-THC concentration in serum and oral fluid: Limits of impairment
→
Get in Touch
We are always up for communicating with people that have interesting ideas or questions. If you want to contact our department, please reach out using this form below.